Efficacy of targeted therapy in early-relapsing FL (POD24)
| Agent . | Overall Response, % . | PFS . | OS . | Reference . |
|---|---|---|---|---|
| Lenalidomide rituximab (n = 43) | 48 | 50% (1 y) | NA | 40 |
| Lenalidomide obinutuzumab (n = 24) | 67 | 75% (1 y) | 87% (1 y) | 41 |
| Idelalisib (n = 37) | 57 | 11 mo (median) | NA | 46 |
| Copanlisib (n = 93)* | 58 | 11 mo (median) | 43 mo (median) | 46,,-49 |
| Agent . | Overall Response, % . | PFS . | OS . | Reference . |
|---|---|---|---|---|
| Lenalidomide rituximab (n = 43) | 48 | 50% (1 y) | NA | 40 |
| Lenalidomide obinutuzumab (n = 24) | 67 | 75% (1 y) | 87% (1 y) | 41 |
| Idelalisib (n = 37) | 57 | 11 mo (median) | NA | 46 |
| Copanlisib (n = 93)* | 58 | 11 mo (median) | 43 mo (median) | 46,,-49 |
NA, not applicable.
FL and marginal zone lymphoma patients.